Publications & Presentations That Leverage Our Technology

January 2021
Volume 20, 100111

Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation

August 2021
Volume 27, Issue 15

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

April 2021
J Pignon et al.

Investigating the potential clinical predictive value of virus genotype, menopausal status and mutational landscape in cervical cancer tissue using a NGS based human papillomavirus (HPV) assay and whole exome sequencing (WES)

April 2021
R Pyke et al.

Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm

April 2021
C W Abbott et al.

Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy

April 2021
R Pyke et al.

Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework

April 2021
F C P Navarro et al.

Pan-cancer shedding patterns of tumor circulating cell free DNA

April 2021
E Levy et al.

Profiling tumor-infiltrating immune cells using an augmented transcriptome

March 2021
Hubert Lam et al.

An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.

January 2021
O’Hara, Mark H et al.

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

November 2020

Feng Z, Scheuenpflug J, Tan M et al.

Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients.

October 2020
Ott, Patrick A et al.

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

September 7, 2020
Motzer, RJ, Robbins, PB, Powles, T et al.

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

January 2020
Herrera AF, Goy A, Mehta A et al.

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

September 1, 2019
Lowery, Maeve A et al.

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

December 09, 2016
Dimopoulos, Meletios A et al.

Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

August 2016
Ashley, E

Towards precision medicine.

July 2015
Patwardhan, A, Harris, J, Leng, N et al.

Achieving high-sensitivity for clinical applications using augmented exome sequencing.